Myeloproliferative Neoplasms (MPNs) Patient Registry

Titre officiel

Clinical and Molecular Epidemiology of Myeloproliferative Neoplasms (MPNs)


Le mandat de ce registre MPN est de recueillir des renseignements cliniques, y compris des résultats moléculaires, auprès de patients consentants présentant une variété de néoplasies myéloprolifératives, à différents stades au cours de leur maladie.

Description de l'essai

Primary Outcome:

  • Survival
Secondary Outcome:
  • General patient characteristics will be captured from the Hematologic Malignancy tissue bank
  • Disease risk score
  • Quality of life - Neoplasm Symptom
  • Co-morbidities
  • Physical symptoms of MPN
  • MPN treatment type received
  • Transfusion dependence status
  • Current Blood Work
  • Identifying MPN driver mutations by using next generation sequencing.
  • Bone marrow transplant details (if received)
  • Bone marrow transplant complications (if received)
  • Portal hypertension
  • Pulmonary hypertension
  • Thrombosis
  • Family history of MPN will be obtained from the patient record.
  • Disease progression
The myeloproliferative neoplasms (MPNs) are a group of rare hematological malignancies in which the bone marrow cells that produce the body's blood cells develop and function abnormally. Despite the gains that have already been made in understanding and treatment of MPNs there is much that can still be learned. This registry will establish a clinical annotation database would help to better understand this group of diseases and to more effectively assign individual patients to the optimal therapy and so, improve their outcomes. This project will provide new insights on the molecular profiling of patients with MPN. It will be used as future resource for observational studies related to MPN. The registry involves the collection of clinical information from patients with diagnosis of MPN at different time points during the course of their disease. The clinical data is collected following written informed consent from the Hematologic Malignancy tissue bank (UHN REB 01-0573C). Data collected includes: a range of clinical measures, disease-associated factors, details of treatment and its results, complications during treatment, molecular and cytogenetic data, symptom assessment and survival outcome (up to 10 years). Data will be collected prospectively and retrospectively, in both cases after obtaining written informed consent as per the study standard operating procedure (SOP).

Voir cet essai sur

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.


Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer